Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHB-137 in Combination With Hepatitis B Vaccine or Peg-IFN in HBeAg-Negative Chronic Hepatitis B
NCT07069569Phase 2Recruiting
- Sponsor
- AusperBio
- Start
- Jun 2025
- Primary completion
- Jul 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of AHB-137 in Chronic Hepatitis B (CHB), sponsored by AusperBio. Started Jun 2025; status: recruiting.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07069569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069569.